S-2E is a compound that functions as an orally active, noncompetitive inhibitor of both HMG-CoA reductase and acetyl-CoA carboxylase. It exhibits an anti-hyperlipidemic action, making it suitable for studying conditions such as familial hypercholesterolemia and mixed hyperlipidemia [1] [2].

In the liver, S-2E is converted into its active metabolite, S-2E-CoA. S-2E-CoA noncompetitively inhibits the enzymatic activities of both 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase and acetyl-CoA carboxylase at K i =18.11 μM and K i =69.2 μM, respectively [1]. S-2E (3-30 mg/kg) given orally suppresses the secretion rate of very-low-density lipoprotein (VLDL)-cholesterol and triglyceride in Triton WR-1339-injected rats. Furthermore, S-2E lowers the blood total cholesterol and triglyceride levels simultaneously in Zucker fatty rats [1].